NCT03207126

Brief Summary

Aim: Assess accuracy of histological diagnosis using ultrasound guided biopsy for women with suspected endometrial cancer (as an alternative to hysteroscopy guided biopsy). All women presenting to clinic with suspected endometrial cancer will have an internal ultrasound. If the endometrial lining is thickened an endometrial biopsy will be performed. This can sometimes be done in an outpatient clinic, or sometimes a hysteroscopy and biopsy is needed (on a different day). Hysteroscopy guided biopsy has the advantage of enabling the clinician to perform directed biopsies under vision. Ultrasound guided biopsy is a ubiquitous procedure when used elsewhere in the body however it is not routinely used in this context. It does have the advantage of being easily performed on the same day as the first consultation. In this pilot study the diagnostic ability and tolerability of ultrasound guided biopsy of women with suspected cancer will be assessed as an alternative to hysteroscopy guided biopsy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 13, 2017

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

June 30, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 2, 2017

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
4.9 years until next milestone

Results Posted

Study results publicly available

November 25, 2024

Completed
Last Updated

November 25, 2024

Status Verified

October 1, 2024

Enrollment Period

2.6 years

First QC Date

June 30, 2017

Results QC Date

April 15, 2024

Last Update Submit

October 4, 2024

Conditions

Keywords

UltrasoundBiopsyEndometrial cancer

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Whose Sample Was Successfully Analysed by Histological Diagnosis

    All samples taken using ultrasound guided biopsy were analysed by histology lab. If they had sufficient tissue to give a diagnosis (benign, pre-malignant or malignant) this was deemed successful. It is deemed successful if there was sufficient tissue to give a histological analysis. So overall there will be a percentage success rate (number of tissue samples sufficient/number of tissue samples taken). Each patient would have had one sample.

    1.5 years

Secondary Outcomes (1)

  • Patient Satisfaction of Ultrasound Guided Biopsy by Questionnaire

    1.5 years

Study Arms (1)

Women needing endometrial biopsy

OTHER

All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.

Diagnostic Test: Ultrasound guided biopsy

Interventions

For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first

Women needing endometrial biopsy

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsStudy is looking at endometrial cancer
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All women presenting to rapid access gynaecology clinic with postmenopausal bleeding or intermenstrual bleeding or referred with a confirmed diagnosis of endometrial cancer.

You may not qualify if:

  • Anyone lacking capacity. \<18years old. Pregnant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Queen Charlotte and Hammersmith Hospital

London, W12 0HS, United Kingdom

Location

MeSH Terms

Conditions

Endometrial NeoplasmsEndometrial Hyperplasia

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Results Point of Contact

Title
Diana Marcus
Organization
Imperial College London

Study Officials

  • Diana Marcus, MB BS

    Imperial College London

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: Women offered and received ultrasound guided biopsy
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2017

First Posted

July 2, 2017

Study Start

June 13, 2017

Primary Completion

January 1, 2020

Study Completion

January 1, 2020

Last Updated

November 25, 2024

Results First Posted

November 25, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Will share results if published only.

Locations